Guo-Liang Yu, Ph.D.
Advisors and Consultants

Dr. Yu is Chairman and CEO of Apollomics Pharmaceuticals Inc, an innovative therapeutics company devoted to curing cancer by combining immunology and other therapeutic tools. Before Apollomics, he was Executive Chairman of Crown Biosicence Inc. prior to its acquisition by JSR in 2018.  Before Crown Bioscience, he was Chairman and CEO of Epitomics Inc. prior to its acquisition by Abcam in 2012.  Prior positions also include Senior VP of R&D at Mendel Biotechnology Inc., and Senior Scientist at Human Genome Sciences Inc.

Dr. Yu has co-authored 43 peer-reviewed scientific articles that have been referenced by the scientific community over 6,000 times. He is a co-inventor of more than 400 patents. Dr. Yu graduated from Fudan University with B.S in biology and obtained his Ph.D. from the University of California, Berkeley where he and Dr. Carol W. Greider discovered telomerase and its mechanism in Dr. Elizabeth Blackburn’s lab.  Dr. Yu subsequently joined Dr. Frederick Ausubel’s lab at Harvard University as a post-doctoral fellow, where he identified the first plant disease resistance gene. 

© Copyright AceLink Therapeutics. All rights reserved